Clinical Trials · NCT05984134
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Enrollment
- 90
- Start date
- Jul 2022
- Locations
- 1 site, China
- Primary endpoint
- Percentage change of myocardial infarction area